Literature DB >> 24651452

Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.

Melanie A Krook1, Lauren A Nicholls1, Christopher A Scannell1, Rashmi Chugh2, Dafydd G Thomas3, Elizabeth R Lawlor4.   

Abstract

UNLABELLED: Ewing sarcoma is the second most common bone cancer in pediatric patients. Although the primary cause of death in Ewing sarcoma is metastasis, the mechanism underlying tumor spread needs to be elucidated. To this end, the role of the CXCR4/SDF-1a chemokine axis as a mediator of Ewing sarcoma metastasis was investigated. CXCR4 expression status was measured in primary tumor specimens by immunohistochemical staining and in multiple cell lines by quantitative reverse transcriptase PCR and flow cytometry. Migration and invasion of CXCR4-positive Ewing sarcoma cells toward CXCL12/SDF-1a were also determined. Interestingly, while CXCR4 status was disparate among Ewing sarcoma cells, ranging from absent to high-level expression, its expression was found to be highly dynamic and responsive to changes in the microenvironment. In particular, upregulation of CXCR4 occurred in cells that were subjected to growth factor deprivation, hypoxia, and space constraints. This upregulation of CXCR4 was rapidly reversed upon removal of the offending cellular stress conditions. Functionally, CXCR4-positive cells migrated and invaded toward an SDF-1a gradient and these aggressive properties were impeded by both the CXCR4 small-molecule inhibitor AMD3100, and by knockdown of CXCR4. In addition, CXCR4-dependent migration and invasion were inhibited by small-molecule inhibitors of Cdc42 and Rac1, mechanistically implicating these Rho-GTPases as downstream mediators of the CXCR4-dependent phenotype. IMPLICATIONS: This study reveals the highly plastic and dynamic nature of CXCR4 expression in Ewing sarcoma and supports a model in which stress-induced upregulation of CXCR4 contributes to tumor metastasis to lung and bone marrow, which express high levels of SDF-1a. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24651452      PMCID: PMC4058379          DOI: 10.1158/1541-7786.MCR-13-0668

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  39 in total

1.  Perspective: The right trials.

Authors:  Patricia S Steeg
Journal:  Nature       Date:  2012-05-30       Impact factor: 49.962

Review 2.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 3.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

4.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma.

Authors:  Libo Zhang; Herman Yeger; Bikul Das; Meredith S Irwin; Sylvain Baruchel
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

Review 6.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation.

Authors:  Alex J Carlisle; Christopher A Lyttle; Rosalind Y Carlisle; John M Maris
Journal:  Mol Cancer       Date:  2009-12-22       Impact factor: 27.401

8.  Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression.

Authors:  Zhe Jin; Chenghai Zhao; Xiaorui Han; Yaxin Han
Journal:  BMC Cancer       Date:  2012-10-18       Impact factor: 4.430

9.  Cysteine (C)-x-C receptor 4 undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells.

Authors:  Ayesha S Don-Salu-Hewage; Siu Yuen Chan; Kathleen M McAndrews; Mahandranauth A Chetram; Michelle R Dawson; Danaya A Bethea; Cimona V Hinton
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  ERBB4 confers metastatic capacity in Ewing sarcoma.

Authors:  Ariadna Mendoza-Naranjo; Amal El-Naggar; Daniel H Wai; Priti Mistry; Nikola Lazic; Fernanda Rocha Rojas Ayala; Isabela Werneck da Cunha; Pablo Rodriguez-Viciana; Hongwei Cheng; Jose H Tavares Guerreiro Fregnani; Patrick Reynolds; Robert J Arceci; Andrew Nicholson; Timothy J Triche; Fernando A Soares; Adrienne M Flanagan; Yuzhuo Z Wang; Sandra J Strauss; Poul H Sorensen
Journal:  EMBO Mol Med       Date:  2013-05-16       Impact factor: 12.137

View more
  34 in total

1.  Heterogeneity of chemokine cell-surface receptor expression in triple-negative breast cancer.

Authors:  Kerri-Ann Norton; Aleksander S Popel; Niranjan B Pandey
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

2.  Menin regulates the serine biosynthetic pathway in Ewing sarcoma.

Authors:  Laurie K Svoboda; Selina Shiqing K Teh; Sudha Sud; Samuel Kerk; Aaron Zebolsky; Sydney Treichel; Dafydd Thomas; Christopher J Halbrook; Ho-Joon Lee; Daniel Kremer; Li Zhang; Szymon Klossowski; Armand R Bankhead; Brian Magnuson; Mats Ljungman; Tomasz Cierpicki; Jolanta Grembecka; Costas A Lyssiotis; Elizabeth R Lawlor
Journal:  J Pathol       Date:  2018-05-28       Impact factor: 7.996

3.  Paracrine Effects of the Pluripotent Stem Cell-Derived Cardiac Myocytes Salvage the Injured Myocardium.

Authors:  Atsushi Tachibana; Michelle R Santoso; Morteza Mahmoudi; Praveen Shukla; Lei Wang; Mihoko Bennett; Andrew B Goldstone; Mouer Wang; Masahiro Fukushi; Antje D Ebert; Y Joseph Woo; Eric Rulifson; Phillip C Yang
Journal:  Circ Res       Date:  2017-07-25       Impact factor: 17.367

4.  Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

Authors:  David M Habiel; Milena S Espindola; Ana L Coelho; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2018-02-17       Impact factor: 4.307

5.  The Ewing Sarcoma Secretome and Its Response to Activation of Wnt/beta-catenin Signaling.

Authors:  Allegra G Hawkins; Venkatesha Basrur; Felipe da Veiga Leprevost; Elisabeth Pedersen; Colin Sperring; Alexey I Nesvizhskii; Elizabeth R Lawlor
Journal:  Mol Cell Proteomics       Date:  2018-01-31       Impact factor: 5.911

Review 6.  Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

Authors:  Elizabeth R Lawlor; Poul H Sorensen
Journal:  Crit Rev Oncog       Date:  2015

7.  Downregulation of CXCR4 in Metastasized Breast Cancer Cells and Implication in Their Dormancy.

Authors:  Kentaro Nobutani; Yohei Shimono; Kiyohito Mizutani; Yuki Ueda; Toshihiro Suzuki; Midori Kitayama; Akihiro Minami; Kenji Momose; Kohta Miyawaki; Koichi Akashi; Takeshi Azuma; Yoshimi Takai
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

Review 8.  Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes.

Authors:  Laurens G L Sand; Karoly Szuhai; Pancras C W Hogendoorn
Journal:  Int J Mol Sci       Date:  2015-07-16       Impact factor: 5.923

9.  Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group.

Authors:  Samuel L Volchenboum; Jorge Andrade; Lei Huang; Donald A Barkauskas; Mark Krailo; Richard B Womer; Andreas Ranft; Jenny Potratz; Uta Dirksen; Timothy J Triche; Elizabeth R Lawlor
Journal:  J Pathol Clin Res       Date:  2015-04

10.  SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction.

Authors:  Jennifer Pasquier; Nadine Abu-Kaoud; Houari Abdesselem; Aisha Madani; Jessica Hoarau-Véchot; Hamda Al Thawadi; Fabien Vidal; Bettina Couderc; Gilles Favre; Arash Rafii
Journal:  BMC Cancer       Date:  2015-08-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.